Lower Drug Prices Now shared recommendations with the Presidential candidates on how to respond to the COVID-19 pandemic and ensure affordable treatments and vaccines for all.
“The explosive report in the New York Times showing that President Trump has financial ties to the company making a version of the experimental drug he is pushing raises serious ethical, moral and legal questions that need to be immediately investigated by Congress. Is Trump personally profiting from this crisis? Is he helping his buddies in the pharmaceutical industry profiteer from the pandemic? Given the all too cozy relationship that his administration has with Big Pharma, these questions need to be thoroughly investigated.”
Front Page Live – 3/26/20
A few weeks ago, Matt Colvin of Tennessee was the subject of massive national outrage. Colvin’s crime? Buying up 17,700 bottles of hand sanitizer and selling them at a massive markup on Amazon. Colvin’s actions were worthy of the outrage. But Americans should direct the bulk of anger at Big Pharma corporations and their allies in the White House. These pharma profiteers are preparing to price gauge COVID-19 patients on a massive scale.
Religion News Service – 3/26/20
OPED by Rev. Liz Theoharris
WASHINGTON (March 26, 2020) – The United States Senate just passed a $2 trillion stimulus bill in response to the coronavirus crisis in the United States. The legislation includes provisions to support hospitals, small businesses and distressed companies caught in the public health and economic fallout from the pandemic.
Washington, DC (March 24, 2020) – Yesterday the Trump Administration gave the drug corporation Gilead Sciences special monopoly protection on the promising COVID-19 treatment Remdesivir, giving them a green light to price gouge on a desperately needed treatment.
WASHINGTON (March 20, 2020) – Since the start of the coronavirus COVID-19 outbreak in the U.S. the Lower Drug Prices Now Coalition has been sounding the alarm about potential Big Pharma price gouging if President Trump and Health and Human Services Secretary Azar fail to enact price control measures that ensure affordability.